Relapse and Rehospitalisation Rates in Patients with Schizophrenia

[1]  M. Olfson,et al.  The Cost of Relapse in Schizophrenia , 2017, PharmacoEconomics.

[2]  片見 真由美,et al.  地域における「家族教室」の取り組み(第1報) : 『こころのビタミン講座』を開催して , 2002 .

[3]  J. Csernansky,et al.  A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. , 2002, The New England journal of medicine.

[4]  J. M. Pierre,et al.  Risperidone-associated new-onset diabetes , 2001, Biological Psychiatry.

[5]  S. Genedani,et al.  Effectiveness of clozapine and olanzapine: a comparison in severe, psychotically ill patients. , 2001, The international journal of neuropsychopharmacology.

[6]  S L Normand,et al.  Partial versus full hospitalization for adults in psychiatric distress: a systematic review of the published literature (1957-1997). , 2001, The American journal of psychiatry.

[7]  P. Keck,et al.  Ziprasidone in the Short-Term Treatment of Patients with Schizoaffective Disorder: Results from Two Double-Blind, Placebo-Controlled, Multicenter Studies , 2001, Journal of clinical psychopharmacology.

[8]  J. Rabinowitz,et al.  Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. , 2001, The American journal of psychiatry.

[9]  N Freemantle,et al.  Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis , 2000, BMJ : British Medical Journal.

[10]  M. Knapp.  Schizophrenia costs and treatment cost‐effectiveness , 2000, Acta psychiatrica Scandinavica. Supplementum.

[11]  D. Revicki,et al.  Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in a European sample , 2000, International clinical psychopharmacology.

[12]  D. Daniel,et al.  Ziprasidone: comprehensive overview and clinical use of a novel antipsychotic , 2000, Expert opinion on investigational drugs.

[13]  S. Purdon.  Measuring neuropsychological change in schizophrenia with novel antipsychotic medications. , 2000, Journal of psychiatry & neuroscience : JPN.

[14]  David Taylor,et al.  Tolerability of Atypical Antipsychotics , 2000, Drug safety.

[15]  M. Olfson,et al.  Predicting medication noncompliance after hospital discharge among patients with schizophrenia. , 2000, Psychiatric services.

[16]  D. Copolov,et al.  A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophrenia , 2000, Psychological Medicine.

[17]  M. Olfson,et al.  Assessing clinical predictions of early rehospitalization in schizophrenia. , 1999, The Journal of nervous and mental disease.

[18]  M. Heo,et al.  Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.

[19]  J J Bartko,et al.  Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. , 1999, The American journal of psychiatry.

[20]  D. Revicki.  Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia , 1999, Schizophrenia Research.

[21]  R. Tamura,et al.  Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol , 1999, British Journal of Psychiatry.

[22]  R. Conley,et al.  Rehospitalization rates for depot antipsychotics and pharmacoeconomic implications: comparison with risperidone. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  S. Marder,et al.  Novel antipsychotics and new onset diabetes , 1998, Biological Psychiatry.

[24]  G. Tollefson,et al.  Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. , 1997, Psychiatric services.

[25]  G. Tollefson,et al.  Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. , 1997 .

[26]  R. Rosenheck,et al.  A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. , 1997, The New England journal of medicine.

[27]  L. Arvanitis,et al.  Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo , 1997, Biological Psychiatry.

[28]  J. Lieberman,et al.  Relapse and rehospitalization during maintenance treatment of schizophrenia. The effects of dose reduction and family treatment. , 1997, Archives of general psychiatry.

[29]  Michael F. Green,et al.  What are the functional consequences of neurocognitive deficits in schizophrenia? , 1996, The American journal of psychiatry.

[30]  A. Lehman,et al.  Quality of life and clinical predictors of rehospitalization of persons with severe mental illness. , 1995, Psychiatric services.

[31]  M. Sullivan,et al.  Drs. Sullivan and Youngner Reply , 1995 .

[32]  D. Jonsson,et al.  Cost‐effectiveness of clozapine treatment in therapy‐refractory schizophrenia , 1995, Acta psychiatrica Scandinavica.

[33]  J L Cavanaugh,et al.  Predicting the "revolving door" phenomenon among patients with schizophrenic, schizoaffective, and affective disorders. , 1995, The American journal of psychiatry.

[34]  N C Andreasen,et al.  Symptoms of Schizophrenia: Methods, Meanings, and Mechanisms , 1995 .

[35]  E. Lindström,et al.  Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. , 1995, Clinical therapeutics.

[36]  S. Marder,et al.  Risperidone in the treatment of schizophrenia. , 1994, The American journal of psychiatry.

[37]  W. Faustman,et al.  Correlations Between Akathisia and Residual Psychopathology: A By-product of Neuroleptic-Induced Dysphoria , 1994, British Journal of Psychiatry.

[38]  P. Yellowlees,et al.  Psychiatric and social reasons for frequent rehospitalization. , 1994, Hospital & community psychiatry.

[39]  S. Marder,et al.  A one-year comparison of four dosages of haloperidol decanoate , 1993, Schizophrenia Research.

[40]  R. Buchanan,et al.  Clozapine in schizophrenic outpatients: Efficacy, longterm outcome, and relationship to prefrontal cortex , 1993, Schizophrenia Research.

[41]  A Labelle,et al.  A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. , 1993, Journal of clinical psychopharmacology.

[42]  G. Sedvall,et al.  Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. , 1992, Archives of general psychiatry.

[43]  W. Buis.  Patients' opinions concerning side effects of depot neuroleptics. , 1992, The American journal of psychiatry.

[44]  J. Peuskens,et al.  Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double‐blind comparative study , 1992, Acta psychiatrica Scandinavica.

[45]  G. Honigfeld,et al.  A two-year clinical and economic follow-up of patients on clozapine. , 1990, Hospital & community psychiatry.

[46]  H. Meltzer,et al.  Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. , 1990, Hospital & community psychiatry.

[47]  G. Simpson,et al.  Fluphenazine dose, clinical response, and extrapyramidal symptoms during acute treatment. , 1990, Archives of general psychiatry.

[48]  S. Marder,et al.  A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. , 1990, Archives of general psychiatry.

[49]  J. Goldstein,et al.  Gender differences in schizophrenia: rehospitalization and community survival , 1989, Psychological Medicine.

[50]  J. McEvoy,et al.  Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. , 1988, Archives of general psychiatry.

[51]  G Honigfeld,et al.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. , 1988, Archives of general psychiatry.

[52]  S. Marder,et al.  Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome. , 1987, Archives of general psychiatry.

[53]  J. Davis,et al.  Maintenance therapy and the natural course of schizophrenia. , 1985, The Journal of clinical psychiatry.

[54]  R. Drake,et al.  Suicide attempts associated with akathisia. , 1985, The American journal of psychiatry.

[55]  J. Fleiss,et al.  Rehospitalization in Chronic Schizophrenia , 1985, The Journal of nervous and mental disease.

[56]  A. Rifkin,et al.  Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates. , 1983, Archives of general psychiatry.

[57]  S. Gore,et al.  Clinical Characteristics of Akathisia , 1983, British Journal of Psychiatry.

[58]  W. Keckich.  Neuroleptics. Violence as a manifestation of akathisia. , 1978, JAMA.

[59]  R. A. May,et al.  Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. , 1978, Archives of general psychiatry.

[60]  T. Putten,et al.  Drug refusal in schizophrenia and the wish to be crazy. , 1976, Archives of general psychiatry.

[61]  Singh Mm.  Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. , 1976 .

[62]  T. Putten.  Why do schizophrenic patients refuse to take their drugs , 1974 .

[63]  L. Kalinowsky.  Appraisal of the tranquilizers and their influence on other somatic treatments in psychiatry. , 1958, The American journal of psychiatry.

[64]  L. Adler,et al.  Neuroleptic-induced akathisia: a review , 2004, Psychopharmacology.

[65]  V. Lee,et al.  Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. , 2002, Clinical therapeutics.

[66]  N. Sussman,et al.  Review of atypical antipsychotics and weight gain. , 2001, The Journal of clinical psychiatry.

[67]  D. Henderson.  Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. , 2001, The Journal of clinical psychiatry.

[68]  D. Perkins.  Adherence to antipsychotic medications. , 1999, The Journal of clinical psychiatry.

[69]  W. Gaebel,et al.  Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. , 1998, Schizophrenia bulletin.

[70]  Julie Kreyenbuhl,et al.  Practice guideline for the treatment of patients with schizophrenia , 1997 .

[71]  H. Morgenstern,et al.  Identifying modifiable risk factors for rehospitalization: a case-control study of seriously mentally ill persons in Mississippi. , 1995, The American journal of psychiatry.

[72]  N. Schooler.  Maintenance Medication for Schizophrenia: Strategies for Dose Reduction , 1991 .

[73]  H. Wittchen,et al.  Risk of Rehospitalization of Psychotic Patients , 1987 .